Literature DB >> 18361418

The human retinitis pigmentosa GTPase regulator gene variant database.

Xinhua Shu1, Ewan McDowall, Alastair F Brown, Alan F Wright.   

Abstract

X-linked retinitis pigmentosa (XLRP) is a genetically heterogeneous retinal degeneration. The major subtype of XLRP is RP3, which accounts for 6 to 20% of all RP cases. Mutations in the RP3 gene, called RP GTPase regulator (RPGR), cause a number of different retinopathies. An RPGR database has been created using the Leiden Open Source Variation Database (LOVD) software system and has comprehensive search and analysis tools. This database is a central resource of RPGR sequence variant data for investigators and will facilitate the interpretation of new mutations, variants, and polymorphisms when these are identified in patients. The database is available on the Internet (http://rpgr.hgu.mrc.ac.uk).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361418     DOI: 10.1002/humu.20733

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

1.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

2.  Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP.

Authors:  Qihong Zhang; Joseph C Giacalone; Charles Searby; Edwin M Stone; Budd A Tucker; Val C Sheffield
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-08       Impact factor: 11.205

3.  What's in a name? RPGR mutations redefine the genetic and phenotypic landscape in retinal degenerative diseases.

Authors:  Anand Swaroop
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-19       Impact factor: 4.799

4.  Identification of disease-causing mutations in autosomal dominant retinitis pigmentosa (adRP) using next-generation DNA sequencing.

Authors:  Sara J Bowne; Lori S Sullivan; Daniel C Koboldt; Li Ding; Robert Fulton; Rachel M Abbott; Erica J Sodergren; David G Birch; Dianna H Wheaton; John R Heckenlively; Qin Liu; Eric A Pierce; George M Weinstock; Stephen P Daiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-25       Impact factor: 4.799

Review 5.  Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait.

Authors:  Alan F Wright; Christina F Chakarova; Mai M Abd El-Aziz; Shomi S Bhattacharya
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

6.  Evolutionary Characterization of the Retinitis Pigmentosa GTPase Regulator Gene.

Authors:  Rakesh Kotapati Raghupathy; Philippe Gautier; Dinesh C Soares; Alan F Wright; Xinhua Shu
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

Review 7.  The Role of RPGR and Its Interacting Proteins in Ciliopathies.

Authors:  Sarita Rani Patnaik; Rakesh Kotapati Raghupathy; Xun Zhang; David Mansfield; Xinhua Shu
Journal:  J Ophthalmol       Date:  2015-06-01       Impact factor: 1.909

8.  Quantitative Analysis of Retinal Structure Using Spectral-Domain Optical Coherence Tomography in RPGR-Associated Retinopathy.

Authors:  James J L Tee; Joseph Carroll; Andrew R Webster; Michel Michaelides
Journal:  Am J Ophthalmol       Date:  2017-03-18       Impact factor: 5.258

Review 9.  Molecular Strategies for RPGR Gene Therapy.

Authors:  Jasmina Cehajic Kapetanovic; Michelle E McClements; Cristina Martinez-Fernandez de la Camara; Robert E MacLaren
Journal:  Genes (Basel)       Date:  2019-09-04       Impact factor: 4.096

10.  De Novo Assembly-Based Analysis of RPGR Exon ORF15 in an Indigenous African Cohort Overcomes Limitations of a Standard Next-Generation Sequencing (NGS) Data Analysis Pipeline.

Authors:  Jordi Maggi; Lisa Roberts; Samuel Koller; George Rebello; Wolfgang Berger; Rajkumar Ramesar
Journal:  Genes (Basel)       Date:  2020-07-15       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.